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A B S T R A C T   
TREK and TRESK K2P channels are widely expressed in the nervous system, particularly in sensory neurons, 
where they regulate neuronal excitability. In this study, using whole-cell patch-clamp electrophysiology, we 
characterise the inhibitory effect of the anticonvulsant lamotrigine and two derivatives, sipatrigine and 3,5-dia-
mino-6-(3,5-bistrifluoromethylphenyl)-1,2,4-triazine (CEN-092) on these channels. 
Sipatrigine was found to be a more effective inhibitor than lamotrigine of TREK-1, TREK-2 and TRESK 
channels. Sipatrigine was slightly more potent on TREK-1 channels (EC50 = 16 μM) than TRESK (EC50 = 34 μM) 
whereas lamotrigine was equally effective on TREK-1 and TRESK. Sipatrigine was less effective on a short iso-
form of TREK-2, suggesting the N terminus of the channel is important for both inhibition and subsequent over- 
recovery. Inhibition of TREK-1 and TREK-2 channels by sipatrigine was reduced by mutation of a leucine residue 
associated with the norfluoxetine binding site on these channels (L289A and L320A on TREK-1 and TREK-2, 
respectively) but these did not affect inhibition by lamotrigine. Inhibition of TRESK by sipatrigine and lamo-
trigine was attenuated by mutation of bulky phenylalanine residues (F145A and F352A) in the inner pore helix. 
However, phosphorylation mutations did not alter the effect of sipatrigine. CEN-092 was a more effective in-
hibitor of TRESK channels than TREK-1 channels. 
It is concluded that lamotrigine, sipatrigine and CEN-092 are all inhibitors of TREK and TRESK channels but 
do not greatly discriminate between them. The actions of these compounds may contribute to their current and 
potential use in the treatment of pain and depression.   
1. Introduction 
The TWIK-related potassium channels (TREK-1 and TREK-2) and 
TWIK-related spinal cord potassium channel (TRESK) belong to the two- 
pore domain (K2P) family of ion channels, whose main functional role is 
to regulate cellular excitability [1]. TREK-1 and TREK-2 are highly 
expressed in small nociceptor dorsal root ganglion (DRG) and have been 
shown to play an active role in neuroprotection, schizophrenia, 
depression, and pain, whilst TRESK, with similar high expression in 
sensory neurons, has a role in nociception and migraine [1–4]. Com-
pounds which alter the activity of these channels are therefore predicted 
to have therapeutic potential in treating CNS disorders. Indeed, TREK-1 
and TREK-2, channel activity has been shown to be regulated by anti-
depressants, antipsychotics, mood stabilizers, anaesthetics and neuro-
protective agents [4–9]. TRESK channels have been shown to be 
regulated by volatile anaesthetics [10], anti-depressant and 
anti-convulsant agents [11] and antihistamines [12]. 
Sipatrigine (BW 619C89) is a known neuroprotective agent derived 
from the clinically used antiepileptic agent lamotrigine [13]. Sipatrigine 
has previously been shown to be a potent antagonist of TREK-1, and to a 
lesser extent, TRAAK channels [5,14]. Lamotrigine also modulates 
neuronal activity and is used both as an anti-convulsant agent and in the 
treatment of bipolar disorder [15]. Lamotrigine has previously been 
shown to be an antagonist of TRESK channels [11] with little effect on 
TREK-1 or TRAAK currents [5]. As a result, lamotrigine has been used to 
distinguish TRESK channels from other channels in functional experi-
ments [10,16]. 
More recent advances have revealed possible mechanisms by which 
some modulators of K2P channels activity may act. The co-crystallised 
structure of TREK-2 with norfluoxetine has shown multiple activation 
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states with distant fenestration regions and key “contact points” within 
them [17]. Furthermore, molecular docking simulations and homology 
modelling has identified two key residues in TRESK channels, involved 
in binding blockers of K channels, such as propafenone and lidocaine 
[18]. Alanine mutations of the identified amino acids in TRESK channels 
diminished inhibition by the TRESK blockers quinine, propafenone, 
lidocaine and aristolochic acid [12,19]. 
In this study, we determine the relative pharmacological effects of 
sipatrigine and lamotrigine on human TRESK, TREK-1 and TREK-2 
channels. We further characterise the effect of these compounds utilizing 
reported binding site mutations to try to gain insight into their binding 
and/or mechanism of action. Additionally, for the first time, we describe 
and characterise the effect of a novel lamotrigine-derived compound, 3,5- 
diamino-6-(3,5-bistrifluoromethylphenyl)-1,2,4-triazine (CEN-092) on 
TREK-1 and TRESK channels. 
2. Materials and Methods 
Most of the methods used here have been described previously [20, 
21] and a detailed explanation can be found in Ref. [22]. A summary of 
the methods used and any variations specific to this study are given 
below. 
2.1. Mammalian expression plasmids 
Human TREK-1 (KCNK2, Genbank™ NP_055032.1) and TREK2 
(KCNK10, NP_612190.1) was cloned into pcDNA3.1+ (Invitrogen, 
Carlsbad, CA, USA) and PCMV6-XL-4 (OriGene Technologies, Inc. USA). 
Human TRESK (KCNK18, NP_862823.1) was cloned into pFAW-Ac-GFP 
vector and was a kind gift from Dr Eddie Stevens, Pfizer, UK. 
2.2. Mutations 
Point mutations were introduced into TREK-1, TREK-2 and TRESK by 
site-directed mutagenesis using the QuikChange (Agilent, CA, USA) 
method as previously described [20]. All constructs were fully 
sequenced to ensure correct mutation incorporation (Eurofins MWG 
Operon, Ebersberg, Germany). To generate the N-terminally truncated 
alternative translation initiation (ATI) isoforms of TREK-2: short 
(TREK-2_Δ1-63; 471 amino acids (AA)) and intermediate 
(TREK-2_Δ1-63_M72I; 483 AA) a deletion and site-directed mutagenesis 
strategy (Quikchange, Agilent, CA, USA) was utilised. For the forced 
full-length TREK-2 construct (543 AA), methionine 60 (M60) and M72 
were mutated to isoleucine (I). 
2.3. In silico channel mutation 
The crystal structure of hTREK-1 (PDB ID: 4TWK) was visualised 
using PyMol v1.7 and Modeller v9.18. To create the mutation in the 
model, a residue mutation model script was used [23]. 
2.4. Cell culture 
All experiments were performed using a modified human embryonic 
kidney 293 cell line, tsA201 (European Collection of Authenticated Cell 
Cultures; Sigma-Aldrich, UK), prepared and maintained as previously 
described [20]. 
2.5. Transfection 
All WT and mutant constructs, including a green fluorescent protein 
(GFP)-expressing vector, were transiently transfected at a concentration 
of 0.5 μg, into tsA201 cells, using a modified calcium-phosphate trans-
fection method [20,22]. 
2.6. Whole-cell patch-clamp electrophysiology 
Recordings were made from GFP-fluorescing tsA201 cells, expressing 
the protein of interest using whole-cell patch-clamp in a voltage clamp 
configuration. Whole–cell currents were recorded from cells maintained 
at a holding potential of − 60 mV at 20–24 ◦C (room temperature). A 
combined voltage-step and voltage-ramp protocol was applied using an 
Axopatch 200B patch-clamp amplifier (Molecular Devices, Sunnyvale, 
CA). Cells were first hyperpolarized to − 80 mV for 100 ms and then 
stepped to − 40 mV for 500 ms, then stepped to − 120 mV for 100 ms (the 
“voltage-step” component). This was followed by a 500-ms ramp change 
in voltage to +20 mV and a step back to − 80 mV for another 100 ms 
before being returned to the holding potential of − 60 mV (the “voltage- 
ramp” component). This protocol was composed of sweeps lasting 1.5 s 
(s), including sampling at the holding voltage and was repeated once 
every 5 s. For all experiments, the external recording solution comprised 
of 145 mM NaCl, 2.5 mM KCl, 3 mM MgCl2, 1 mM CaCl2 and 10 mM 
HEPES (pH to 7.4, using NaOH). The internal recoding solution con-
tained 150 mM KCl, 3 mM MgCl2, 5 mM EGTA and 10 mM HEPES (pH 
adjusted to 7.4 with KOH). 
2.7. Compounds 
Sipatrigine and lamotrigine were purchased from Tocris. Cen-092 
was supplied by Dr Mike Leach (University of Greenwich). The com-
pound stock solutions were made up in 100% DMSO or ethanol. 
2.8. Data analysis and statistics 
Current obtained was analysed using pClamp 10.2 software (Mo-
lecular Devices). Quantification of compound effects was carried out 
using currents obtained from the voltage-step component of the proto-
col. Any further analysis and statistical tests were performed using 
GraphPad Prism v8.0.1 (Graphpad, USA). Data are expressed as mean 
values with a range of 95% Confidence Intervals (CI) and n represents 
the number of individual cells. Statistical comparisons were made using 
unpaired two-tailed Welch’s t-tests and one-way ANOVA tests with a 
post hoc Dunnett’s or Tukey’s method for multiple comparison test. P <
0.05 was considered statistically significant. 
3. Results & discussion 
3.1. Sipatrigine is a more effective inhibitor than lamotrigine of both 
TREK and TRESK channels 
Our initial experiments sought to determine the pharmacological 
profile of sipatrigine and lamotrigine on TRESK and TREK-1 channels to 
determine if these compounds did indeed show selectivity between 
channels. Utilizing cloned human wildtype (WT) TREK-1 and TRESK 
channels, transiently expressed in tsA201 cells, whole-cell current was 
measured using patch-clamp electrophysiology in the absence and 
presence of sipatrigine and lamotrigine (see Materials and Methods). 
Acute application of sipatrigine (100 μM) resulted in a potent and 
reversible inhibition of TREK-1 by 87% [95% confidence interval: 
85–92; n = 19, Fig. 1A]. Lamotrigine, at the same concentration, had a 
smaller 30% inhibitory effect on TREK-1 channels [95% CI: 11–53; n =
6, Fig. 1B]. Sipatrigine had a 50% effective concentration (EC50) of 16 
μM [95% CI: 12–20] and a Hill slope of 0.82 [95% CI: 0.7–1, Fig. 1C]. 
Sipatrigine (100 μM) caused a substantial, 73%, inhibition of TRESK 
channels [95% CI: 69–82; n = 16, Fig. 1D] whilst the same concentration 
of lamotrigine inhibited TRESK channels by 35% [95% CI: 9–48; n = 8, 
Fig. 1E]. The inhibitory effect of sipatrigine was significantly less on 
TRESK (p < 0.05 [95% CI -17 to − 8]) than was observed for TREK-1, 
with sipatrigine having an EC50 of 34 μM [95% CI: 29–39] and a Hill 
slope of 0.95 [95% CI: 0.8–1, Fig. 1F] on the former. 
Sipatrigine (100 μM) produced a potent, 85% inhibition [95% CI: 
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76–92; n = 10] of TREK-2 channels, which was similar to that seen for 
TREK-1. Interestingly, for TREK-2, we observed a large over-recovery of 
current following compound washout to 201% above baseline [95% CI: 
126–337; n = 7]. This over-recovery of current is similar to that reported 
previously [5], following sipatrigine block of TREK-1 channels. TREK-2 
(and TREK-1) channels undergo alternative translation initiation (ATI) 
in their N terminal domains resulting in the expression of three func-
tionally different isoforms of TREK-2 channels [24–29]. We investigated 
the effect of sipatrigine on the three ATI-variants of TREK-2. Only the 
shortest form of the channel (TREK-2 Δ1-63) demonstrated significant 
alteration in drug response (p < 0.0001) with sipatrigine inhibition 
reduced to 51% [95% CI: 8–84; n = 6]. These data show that the distal 
half of the N terminus is necessary to promote full inhibition of TREK-2 
by sipatrigine. This is similar to results seen with carvedilol inhibition as 
deletion of the N terminus in TREK-2 significantly decreased this com-
pound’s sensitivity [29]. A similar effect has also been shown on the 
short form of TREK-1 (Δ1-52) which showed less sensitivity to inhibition 
by both fluoxetine and pranlukast than WT TREK-1 channels, indicating 
that the N terminus of TREK-1 is involved in regulation of the channel 
[21,28]. 
Over recovery from inhibition was also lost in the shortest isoform of 
TREK-2 suggesting that the N terminus of the channel is also important 
for recovery of channel activity following application of sipatrigine. In 
TREK-1 channels, the N terminus interacts with the protein EBP50 in the 
plasma membrane which stabilises the structure of proteins and leads to 
a gradual run-up of current in the whole-cell configuration [30]. 
Therefore, loss of this interaction in the short form of TREK channels, 
may lead to a change in compound effects on the channel. 
Lamotrigine (100 μM) had a small inhibitory effect on TREK-2 
channels (14% [95% CI: 7–21; n = 10]). This was significantly smaller 
(p < 0.05) than that observed for lamotrigine block of TREK-1 and 
TRESK. 
3.2. Disruption of a known contact drug binding site in the TM4 region of 
TREK-1 (L289A) reduces the magnitude of sipatrigine inhibition 
The co-crystallised structure of TREK-2 with norfluoxetine identified 
a number of amino acids important for compound binding [17] and 
showed that the residue leucine (L) at position 320 in the TM4 region of 
the channel is important for the binding and the inhibitory effect of 
norfluoxetine. The equivalent amino acid on TREK-1 (L289) (Fig. 2A) 
has recently been shown to contribute to the binding site for the TREK-1 
activator BL-1249 and mutation of this residue reduces the effectiveness 
of the compound [31]. To determine if these sites were also important 
for sipatrigine and lamotrigine binding, we mutated L289 on TREK-1 
and L320 on TREK-2 to an alanine (A). The inhibitory effect of sipa-
trigine (100 μM) on the TREK-1 L289A mutated current was signifi-
cantly attenuated (56% [95% CI: 47–80; n = 9]), compared to the WT 
(87% [95% CI: 85–92; n = 19], p < 0.01). However, the inhibitory effect 
of lamotrigine (100 μM) remained unaffected by the mutation (31% 
[95% CI: 9–67; n = 6]) compared to the WT (30% [95% CI: 12–53; n =
6], p > 0.05, Fig. 2B). The inhibitory effect of sipatrigine (100 μM) on 
the equivalent mutation in TREK-2 (L320A) was also significantly 
reduced (67% [95% CI: 58–71; n = 9]) compared to WT (85% [95% CI: 
76–92; n = 10], p < 0.001). 
Therefore, it is suggested that equivalent leucine residue in both 
TREK-1 and TREK-2 channels is a determinant of sipatrigine binding, 
however, the same mutation in TREK-1 showed no change in the degree 
of lamotrigine inhibition. Thus, there is a difference in the “contact 
points” required for binding of these compounds to TREK channels. 
We also investigated the effect of sipatrigine (100 μM) on a known 
gain-of-function (GOF) mutation of TREK-1, E306A [32], which has 
been shown to affect the magnitude of fluoxetine inhibition [6]. Sipa-
trigine (100 μM) inhibition of the E306A GOF mutation was 64% [95% 
CI: 48–74; n = 7] which was significantly less (p < 0.001) compared to 
Fig. 1. Inhibition of TREK-1 and TRESK channels by sipatrigine (blue) and lamotrigine (green). (A) Current-voltage relationship for TREK-1 in the presence and 
absence of sipatrigine (100 μM) obtained using the voltage-ramp protocol. Insert shows chemical structure of sipatrigine. (B) Current-voltage relationship for TREK-1 
in the presence and absence of lamotrigine (100 μM). Insert shows chemical structure of lamotrigine. (C) Concentration-response curve for sipatrigine inhibition of 
TREK-1 current. (D) Current-voltage relationship for TRESK in the presence and absence of sipatrigine (100 μM). (E) Current-voltage relationship for TRESK in the 
presence and absence of lamotrigine (100 μM). (F) Concentration-response curve for sipatrigine inhibition of TRESK current. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the Web version of this article.) 
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WT TREK-1 current inhibition. Previous studies have shown that E306A 
mutation reduced the fluoxetine inhibitory effect due to the channel 
coupling to the membrane bilayer and entering the open-up state [6, see 
also 17]. Taken together, these results show that specific amino acids in 
the TM4 region of TREK channels are important for compound activity. 
In this study, we provide evidence of a similar mechanism of block by 
sipatrigine to that described for fluoxetine, since inhibition is reduced by 
mutations that alter the fluoxetine binding site in TREK channels 
(L289A, L320A) and by the GOF mutation (E306A), that reduced inhi-
bition by fluoxetine [6]. Taken together these data suggest that, like 
norfluoxetine, sipatrigine binds preferentially to the fenestration site on 
the channel revealed by the M4 down state [17,33] and that block is 
gating-state dependent [6,34]. Since there is known to be more than one 
structurally distinct open state of TREK channels [34], one might spec-
ulate that the over recovery from block (see also [5]), when sipatrigine 
leaves the fenestration site, is due to the channel preferentially entering 
an open state with a high Po, which is influenced by the N terminus of 
the channel, before eventual re-equilibration to the resting level of 
channel activity seen before application of sipatrigine. 
3.3. Mutations in the central cavity of TRESK attenuate sipatrigine and 
lamotrigine inhibition 
For TRESK channels, the presence of bulky, phenylalanine (F) resi-
dues, F145 and F352, named the TM2.6 and TM4.6 residues, is unique 
for mammalian K2P channels [35,36]. It is suggested that these amino 
acids are exposed to a cytoplasmic vestibule in the inner pore region of 
the channel and that a mutation to a less bulky residue, such alanine, 
will diminish this exposure [18]. In agreement with our previous work 
[35] mutation of both these residues (F145A_F352A) results in a 
significantly increased current density (134 pA pF− 1 [95% CI: 81–205; n 
= 13]), compared to WT (65 pA pF− 1 [95% CI: 51–78; n = 28]) (Fig. 3A) 
(p < 0.01). This double F mutation was also found to significantly 
attenuate (p < 0.0001) the inhibitory effects of both sipatrigine (10% 
[95% CI: 4–17; n = 9]) and lamotrigine (5% [95% CI: 2 – 11; n = 11]) at 
a concentration of 100 μM (Fig. 3B). 
These amino acids on TRESK channels have been suggested to be 
potential binding sites for channel blockers quinine, propafenone, 
lidocaine and loratadine [12,18]. However, the increase in basal cur-
rent, [see also 35, 36] and the wide variety of structurally distinct 
molecules affected by mutation of these residues, suggests it is more 
likely that these mutations alter channel gating and indirectly occlude 
compound action rather than directly blocking the binding of the 
compounds. 
3.4. The phosphorylation state of TRESK channel does not influence 
sipatrigine sensitivity 
We considered whether sipatrigine inhibition of the TRESK channel 
was phosphorylation state dependent. The serine (S) residues (S252 and 
S264) have been identified as important sites for phosphorylation/ 
dephosphorylation dependent regulation of TRESK channels [37]. Sub-
stitution of these residues to alanine alters the channel to mimic a 
“dephosphorylated” state, as the serine residues now cannot be phos-
phorylated. Alternatively, substituting these serine residues to a nega-
tively charged glutamic acid (E) is thought to mimic a permanent 
“phosphorylated” channel state [37]. The “dephosphorylated” TRESK 
channel S252A_S264A (AA) had a significantly larger (p < 0.05) current 
density (95 pA pF− 1 [95% CI: 68–122; n = 14]) than the WT channel (65 
pA pF− 1 [95% CI: 51–78; n = 28]). Whilst the phosphorylated 
Fig. 2. Effect of sipatrigine and lamotrigine on mutated TREK-1_L289A. (A) Homology model of human channel TREK-1 (based on PDB: 4TWK) highlighting location 
of mutated residue L289A (red) and TM4 region in green. (B) TREK-1 WT inhibition compared to TREK-1 L289A with sipatrigine and lamotrigine at a concentration 
of 100 μM (**p < 0.01). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
Fig. 3. Effects of TRESK mutations on current density and sipatrigine inhibition. (A) Current density (pA pF− 1) of WT and mutated TRESK channels (B) Sipatrigine 
(100 μM) inhibition of TRESK WT compared to TRESK FF, TRESK AA and TRESK EE (*p < 0.05, **p < 0.01, ****p < 0.0001). 
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S252E_S264E (EE) fixed channel had a similar (p > 0.05) current density 
to WT (80 pA pF− 1 [95% CI: 49–104, n = 15]) (Fig. 3A). The inhibition 
by sipatrigine (100 μM) of the two fixed states were similar (p > 0.05) to 
that for TRESK WT with an inhibition of 70% [95% CI: 54–81; n = 6] for 
the TRESK AA channel and 79% [95% CI: 72–84; n = 6] for TRESK EE 
channel (see Fig. 3B). 
3.5. Characterisation of CEN-092 on TRESK and TREK-1 
CEN-092 is one of a group of compounds developed as sodium 
channel blockers and shown, more recently, to be effective inhibitors of 
IFN gamma secretion [38]. CEN-092 (100 μM), which is derived from 
lamotrigine (Fig. 4A), inhibited TRESK current by 43% [95% CI: 31–54; 
n = 9], similar to the inhibition seen with lamotrigine. Furthermore, the 
TRESK FF mutated channel, significantly attenuated (p < 0.01) the 
magnitude of effect of CEN-092 (12% [95 CI: 1–33; n = 6]). The degree 
of inhibition by CEN-092 showed no significant difference (p > 0.05), 
between the WT and the two phosphorylated states of the channel 
(TRESK AA 49% [95% CI: 21–65; n = 6] and TRESK EE 45% [95% CI: 
31–65; n = 8]), similar to that observed for sipatrigine inhibition 
(Fig. 4C). Inhibition of TREK-1 current by CEN-092 (100 μM) was 21% 
[95% CI: 5–30; n = 9), which was significantly lower than inhibition of 
TRESK at the same concentration (p < 0.01) (Fig. 4D). 
Taken together, sipatrigine is the most potent of the three com-
pounds and shows a small degree of selectivity for TREK channels over 
TRESK. Lamotrigine and the novel compound CEN-092, on the other 
hand, are less effective inhibitors of all three channels tested, but CEN- 
092 is significantly more effective at inhibiting TRESK than TREK 
channels. Given the paucity of selective antagonists of K2P channels [4], 
this study helps clarify the action of sipatrigine and lamotrigine on TREK 
and TRESK channels and, through, the comparative selectivity for the 
novel blocking agent CEN-092 for TRESK over TREK channels provides 
the potential for the development of more selective blocking agents in 
the future. 
The putative importance of TREK and TRESK channels in pain sig-
nalling, suggests that pharmacological modulation which upregulates 
these channels may be a novel strategy for analgesia [4,39,40]. How-
ever, there are known analgesics which inhibit TRESK channels 
including acetaminophen, ibuprofen and nabumetone [41]. The mean 
plasma level of lamotrigine, which is currently used for trigeminal pain, 
in patients was 23 μM (5.9 mg/ml) with an upper level of 70 μM (18.1 
mg/ml) [42] which would cause significant block of both TRESK and 
TREK channels in these patients. 
Analgesics from traditional medicine such as aristolochic acid and 
hydroxyl-α-sanshool, the active ingredient of Szechuan peppers, have 
also been shown to block TRESK channels [19]. The effect of hydrox-
yl-α-sanshool is believed to be caused by desensitising the excitatory 
neurons which leads to a numbing sensation. Thus, it appears that both 
activation and inhibition of TREK and TRESK channels may be beneficial 
in the treatment of pain and there is, perhaps, an optimal level of 
channel activity required to regulate nociceptive neuron excitability. 
There is also significant research which suggests that TREK-1 chan-
nels are involved in depression and a potential target for antidepres-
sants. Deletion of the TREK-1 gene (KCNK2) resulted in a depression- 
resistant phenotype in mice [7]. Several antidepressants are known to 
inhibit TREK-1 channels including fluoxetine and citalopram [9,43]. 
Lamotrigine is already used in patients with depression linked to bipolar 
disorder and has reportedly been used in treatment for patients resistant 
to first line antidepressants. Since sipatrigine is a more potent TREK-1 
channel antagonist than lamotrigine, it could be a more effective 
agent for treating specific forms of depression [44]. 
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